Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance statusCitation formats

  • External authors:
  • Natalie Lowe
  • Jonathan Bernstein
  • Kathleen Mais
  • K. Garcez
  • Lip W. Lee
  • Andrew Sykes
  • David Thomson
  • Jarrod Homer
  • Nicholas Slevin

Standard

Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status. / Lowe, Natalie; Bernstein, Jonathan; Mais, Kathleen; Garcez, K.; Lee, Lip W. ; Sykes, Andrew; Thomson, David; Homer, Jarrod; West, Catharine; Slevin, Nicholas.

In: Journal of Cancer Research and Clinical Oncology, 2017.

Research output: Contribution to journalArticlepeer-review

Harvard

Lowe, N, Bernstein, J, Mais, K, Garcez, K, Lee, LW, Sykes, A, Thomson, D, Homer, J, West, C & Slevin, N 2017, 'Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status', Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-017-2553-9)

APA

Lowe, N., Bernstein, J., Mais, K., Garcez, K., Lee, L. W., Sykes, A., Thomson, D., Homer, J., West, C., & Slevin, N. (2017). Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-017-2553-9)

Vancouver

Author

Lowe, Natalie ; Bernstein, Jonathan ; Mais, Kathleen ; Garcez, K. ; Lee, Lip W. ; Sykes, Andrew ; Thomson, David ; Homer, Jarrod ; West, Catharine ; Slevin, Nicholas. / Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status. In: Journal of Cancer Research and Clinical Oncology. 2017.

Bibtex

@article{0da8360ef6464252b11204b60c32d715,
title = "Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status",
abstract = "PurposeThe benefit of adding docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy to chemoradiotherapy (CRT) in head and neck squamous cell carcinoma (HNSCC) remains uncertain. We aimed to investigate whether ICT is well tolerated when given with prophylactic treatment against predicted adverse effects and which patients benefit most.MethodsA single-centre audit identified 132 HNSCC patients with stage IVa/b neck node-positive disease, prescribed TPF followed by CRT. TPF involved three cycles of docetaxel (75 mg/m2 IV) and cisplatin (75 mg/m2 IV) on day 1 plus 5-FU (750 mg/m2 IV) on days 2–5. Planned CRT was 66 Gy in 30 fractions of intensity-modulated radiotherapy with concurrent cisplatin (100 mg/m2 IV) at the beginning of week 1 and 4 (days 1 and 22). All patients received prophylactic antibiotics and granulocyte colony-stimulating factor.ResultsMedian follow-up was 39.5 months. 92.4% of patients completed three cycles of TPF; 95.5% of patients started chemoradiotherapy. Grade 3/4 adverse events were low (febrile neutropenia 3.0%), with no toxicity-related deaths. 3-year overall survival was 67.2%; disease-specific survival was 78.7%; locoregional control was 78.3%. Distant metastases rate was 9.8% (3.0% in those without locoregional recurrence). Good performance status (p = 0.002) and poor tumour differentiation (p = 0.018) were associated with improved overall survival on multivariate analysis.ConclusionWith prophylactic antibiotics and granulocyte colony-stimulating factor TPF was well tolerated with good survival outcomes. TPF should remain a treatment option for stage IV neck node-positive patients with a good performance status. The use of tumour grade to aid patient selection for TPF warrants investigation.",
author = "Natalie Lowe and Jonathan Bernstein and Kathleen Mais and K. Garcez and Lee, {Lip W.} and Andrew Sykes and David Thomson and Jarrod Homer and Catharine West and Nicholas Slevin",
year = "2017",
doi = "10.1007/s00432-017-2553-9)",
language = "English",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Nature",

}

RIS

TY - JOUR

T1 - Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status

AU - Lowe, Natalie

AU - Bernstein, Jonathan

AU - Mais, Kathleen

AU - Garcez, K.

AU - Lee, Lip W.

AU - Sykes, Andrew

AU - Thomson, David

AU - Homer, Jarrod

AU - West, Catharine

AU - Slevin, Nicholas

PY - 2017

Y1 - 2017

N2 - PurposeThe benefit of adding docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy to chemoradiotherapy (CRT) in head and neck squamous cell carcinoma (HNSCC) remains uncertain. We aimed to investigate whether ICT is well tolerated when given with prophylactic treatment against predicted adverse effects and which patients benefit most.MethodsA single-centre audit identified 132 HNSCC patients with stage IVa/b neck node-positive disease, prescribed TPF followed by CRT. TPF involved three cycles of docetaxel (75 mg/m2 IV) and cisplatin (75 mg/m2 IV) on day 1 plus 5-FU (750 mg/m2 IV) on days 2–5. Planned CRT was 66 Gy in 30 fractions of intensity-modulated radiotherapy with concurrent cisplatin (100 mg/m2 IV) at the beginning of week 1 and 4 (days 1 and 22). All patients received prophylactic antibiotics and granulocyte colony-stimulating factor.ResultsMedian follow-up was 39.5 months. 92.4% of patients completed three cycles of TPF; 95.5% of patients started chemoradiotherapy. Grade 3/4 adverse events were low (febrile neutropenia 3.0%), with no toxicity-related deaths. 3-year overall survival was 67.2%; disease-specific survival was 78.7%; locoregional control was 78.3%. Distant metastases rate was 9.8% (3.0% in those without locoregional recurrence). Good performance status (p = 0.002) and poor tumour differentiation (p = 0.018) were associated with improved overall survival on multivariate analysis.ConclusionWith prophylactic antibiotics and granulocyte colony-stimulating factor TPF was well tolerated with good survival outcomes. TPF should remain a treatment option for stage IV neck node-positive patients with a good performance status. The use of tumour grade to aid patient selection for TPF warrants investigation.

AB - PurposeThe benefit of adding docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy to chemoradiotherapy (CRT) in head and neck squamous cell carcinoma (HNSCC) remains uncertain. We aimed to investigate whether ICT is well tolerated when given with prophylactic treatment against predicted adverse effects and which patients benefit most.MethodsA single-centre audit identified 132 HNSCC patients with stage IVa/b neck node-positive disease, prescribed TPF followed by CRT. TPF involved three cycles of docetaxel (75 mg/m2 IV) and cisplatin (75 mg/m2 IV) on day 1 plus 5-FU (750 mg/m2 IV) on days 2–5. Planned CRT was 66 Gy in 30 fractions of intensity-modulated radiotherapy with concurrent cisplatin (100 mg/m2 IV) at the beginning of week 1 and 4 (days 1 and 22). All patients received prophylactic antibiotics and granulocyte colony-stimulating factor.ResultsMedian follow-up was 39.5 months. 92.4% of patients completed three cycles of TPF; 95.5% of patients started chemoradiotherapy. Grade 3/4 adverse events were low (febrile neutropenia 3.0%), with no toxicity-related deaths. 3-year overall survival was 67.2%; disease-specific survival was 78.7%; locoregional control was 78.3%. Distant metastases rate was 9.8% (3.0% in those without locoregional recurrence). Good performance status (p = 0.002) and poor tumour differentiation (p = 0.018) were associated with improved overall survival on multivariate analysis.ConclusionWith prophylactic antibiotics and granulocyte colony-stimulating factor TPF was well tolerated with good survival outcomes. TPF should remain a treatment option for stage IV neck node-positive patients with a good performance status. The use of tumour grade to aid patient selection for TPF warrants investigation.

U2 - 10.1007/s00432-017-2553-9)

DO - 10.1007/s00432-017-2553-9)

M3 - Article

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

ER -